BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dandri M. Epigenetic modulation in chronic hepatitis B virus infection. Semin Immunopathol 2020;42:173-85. [PMID: 32185454 DOI: 10.1007/s00281-020-00780-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Medhat A, Arzumanyan A, Feitelson MA. Hepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma. Oncotarget 2021;12:2421-33. [PMID: 34853663 DOI: 10.18632/oncotarget.28077] [Reference Citation Analysis]
2 Arechederra M, Recalde M, Gárate-Rascón M, Fernández-Barrena MG, Ávila MA, Berasain C. Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease. Cancers (Basel) 2021;13:1265. [PMID: 33809263 DOI: 10.3390/cancers13061265] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Lucifora J, Baumert TF. Silencing of the HBV episome through degradation of HBx protein: Towards functional cure? Journal of Hepatology 2021;74:497-9. [DOI: 10.1016/j.jhep.2020.10.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Lin Y, Liu Y, Xu D, Guo F, Zhang W, Zhang Y, Bai G. HBxAg promotes HBV replication and EGFR activation in human placental trophoblasts. Exp Ther Med 2021;22:1211. [PMID: 34584556 DOI: 10.3892/etm.2021.10645] [Reference Citation Analysis]
5 Miao J, Gao P, Li Q, He K, Zhang L, Wang J, Huang L. Advances in Nanoparticle Drug Delivery Systems for Anti-Hepatitis B Virus Therapy: A Narrative Review. Int J Mol Sci 2021;22:11227. [PMID: 34681886 DOI: 10.3390/ijms222011227] [Reference Citation Analysis]
6 Zeisel MB, Guerrieri F, Levrero M. Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma. J Clin Med 2021;10:1715. [PMID: 33923385 DOI: 10.3390/jcm10081715] [Reference Citation Analysis]
7 Fischer N. Infection-induced epigenetic changes and their impact on the pathogenesis of diseases. Semin Immunopathol 2020;42:127-30. [PMID: 32318841 DOI: 10.1007/s00281-020-00793-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Zhao K, Liu A, Xia Y. Insights into Hepatitis B Virus DNA Integration-55 Years after Virus Discovery. The Innovation 2020;1:100034. [DOI: 10.1016/j.xinn.2020.100034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
9 Allweiss L, Giersch K, Pirosu A, Volz T, Muench RC, Beran RK, Urban S, Javanbakht H, Fletcher SP, Lütgehetmann M, Dandri M. Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo. Gut 2021:gutjnl-2020-322571. [PMID: 33509930 DOI: 10.1136/gutjnl-2020-322571] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
10 Dandri M, Petersen J. cccDNA Maintenance in Chronic Hepatitis B - Targeting the Matrix of Viral Replication. Infect Drug Resist 2020;13:3873-86. [PMID: 33149632 DOI: 10.2147/IDR.S240472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
11 Di Pietro A. Epstein-Barr Virus Promotes B Cell Lymphomas by Manipulating the Host Epigenetic Machinery. Cancers (Basel) 2020;12:E3037. [PMID: 33086505 DOI: 10.3390/cancers12103037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Dandri M, Bertoletti A, Lütgehetmann M. Innate immunity in hepatitis B and D virus infection: consequences for viral persistence, inflammation, and T cell recognition. Semin Immunopathol 2021. [PMID: 34019142 DOI: 10.1007/s00281-021-00864-x] [Reference Citation Analysis]
13 Martinez MG, Boyd A, Combe E, Testoni B, Zoulim F. Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections. J Hepatol 2021;75:706-17. [PMID: 34051332 DOI: 10.1016/j.jhep.2021.05.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Prieto C, Montecinos J, Jiménez G, Riquelme C, Garrido D, Hernández S, Loyola A, Villanueva RA. Phosphorylation of Phylogenetically Conserved Amino Acid Residues Confines HBx within Different Cell Compartments of Human Hepatocarcinoma Cells. Molecules 2021;26:1254. [PMID: 33652602 DOI: 10.3390/molecules26051254] [Reference Citation Analysis]
15 Moon IY, Kim JW. Methylation profile of hepatitis B virus is not influenced by interferon α in human liver cancer cells. Mol Med Rep 2021;24:715. [PMID: 34396432 DOI: 10.3892/mmr.2021.12354] [Reference Citation Analysis]
16 Francies FZ, Dlamini Z. Aberrant Splicing Events and Epigenetics in Viral Oncogenomics: Current Therapeutic Strategies. Cells 2021;10:239. [PMID: 33530521 DOI: 10.3390/cells10020239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Sartorius K, An P, Winkler C, Chuturgoon A, Li X, Makarova J, Kramvis A. The Epigenetic Modulation of Cancer and Immune Pathways in Hepatitis B Virus-Associated Hepatocellular Carcinoma: The Influence of HBx and miRNA Dysregulation. Front Immunol 2021;12:661204. [PMID: 33995383 DOI: 10.3389/fimmu.2021.661204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Andrisani O. Epigenetic mechanisms in hepatitis B virus-associated hepatocellular carcinoma. Hepatoma Res 2021;7:12. [PMID: 33614973 DOI: 10.20517/2394-5079.2020.83] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Boettler T, Gill US, Allweiss L, Pollicino T, Tavis JE, Zoulim F. Assessing immunological and virological responses in the liver: implications for the cure of chronic hepatitis B virus infection. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100480] [Reference Citation Analysis]
20 de Almeida NAA, de Paula VS. Occult Hepatitis B virus (HBV) infection and challenges for hepatitis elimination: A literature review. J Appl Microbiol 2021. [PMID: 34724308 DOI: 10.1111/jam.15351] [Reference Citation Analysis]
21 Soliman SHA, Orlacchio A, Verginelli F. Viral Manipulation of the Host Epigenome as a Driver of Virus-Induced Oncogenesis. Microorganisms 2021;9:1179. [PMID: 34070716 DOI: 10.3390/microorganisms9061179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Singh P, Kairuz D, Arbuthnot P, Bloom K. Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach. World J Gastroenterol 2021; 27(23): 3182-3207 [PMID: 34163105 DOI: 10.3748/wjg.v27.i23.3182] [Reference Citation Analysis]
23 Ligat G, Goto K, Verrier E, Baumert TF. Targeting Viral cccDNA for Cure of Chronic Hepatitis B. Curr Hepatology Rep 2020;19:235-44. [DOI: 10.1007/s11901-020-00534-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
24 Ligat G, Verrier ER, Nassal M, Baumert TF. Hepatitis B virus-host interactions and novel targets for viral cure. Curr Opin Virol 2021;49:41-51. [PMID: 34029994 DOI: 10.1016/j.coviro.2021.04.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Zhang D, Zhang K, Protzer U, Zeng C. HBV Integration Induces Complex Interactions between Host and Viral Genomic Functions at the Insertion Site. J Clin Transl Hepatol 2021;9:399-408. [PMID: 34221926 DOI: 10.14218/JCTH.2021.00062] [Cited by in F6Publishing: 1] [Reference Citation Analysis]